

CRAN-Related NCI Activities and Research Priorities

*William Klein, Ph.D.
Associate Director
Behavioral Research Program
Division of Cancer Control and Population Sciences*

New NCI Director



Education



UPDATE:

U.S. News & World Report NEWS

Home / News / Health News / Biden to Nominate Head of N...

Biden to Nominate Head of National Cancer Institute to Run NIH

Biden Plans to Nominate Cancer Surgeon to Lead National Institutes of Health

The White House is expected to announce the selection of Dr. Monica M. Bertagnolli, who last year became the director of the National Cancer Institute, in the coming days.

- Member, Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute, Boston
- Cancer researcher

Started Monday, October 3, 2022
First woman to hold the position of NCI Director

CANCER MOONSHOT

- In 2022, President Biden announced a reignition of Cancer MoonshotSM highlighting new goals to reduce the cancer death rate by half within 25 years and improve the lives of those impacted by cancer
- More to be done to:
 - Diagnose cancer sooner
 - Prevent cancer
 - Address inequities
 - Target the right treatments to the right patients
 - Speed progress against the most deadly and rare cancers including childhood cancers
 - Support patients, caregivers, and survivors
 - Learn from all patients

Comment | [Published: 27 June 2022](#)

A new phase of the Cancer Moonshot to end cancer as we know it

[Dinah S. Singer](#) 

[Nature Medicine](#) 28, 1345–1347 (2022)

Cancer Moonshot™:

Accelerate discovery, increase collaboration, and expand data sharing

In the Cancer Moonshot's first 4 years (2017-2021):



Division of Cancer Control and Population Sciences (DCCPS) Crosscutting Areas of Focus



Health Equity



Data Strategies




Modifiable Risk Factors



Climate Change



Evidence-based Policy



Digital Health

Behavioral Research Program (BRP) Organizational Leadership



Dr. William Klein
Associate Director



Dr. Linda Nebeling
Deputy Associate
Director



Dr. Richard Moser
Fellowship Training/
Research Methods
Coordinator



Dr. Paul Han
Senior Scientist



Dr. Paige Green
Basic Biobehavioral and
Psychological Sciences Branch



Dr. Susan Czajkowski
Health Behaviors
Research Branch



Dr. Robin Vanderpool
Health Communication and
Informatics Research Branch



Dr. Neal Freedman
Tobacco Control
Research Branch



Neal Freedman
Ph.D., M.P.H.

Named Chief of the Tobacco
Control Research Branch within
the Behavioral Research Program



Education

- M.P.H., Harvard School of Public Health
- Ph.D., Biomedical Sciences, University of California, San Francisco
- Postdoctoral training: Division of Cancer Epidemiology and Genetics (DCEG) Cancer Prevention Fellowship



Professional History

- Molecular epidemiologist studying the risks of tobacco products and other exposures for cancer and chronic disease
- Tenured senior investigator, Metabolic Epidemiology Branch, DCEG
- Investigator, Nutritional Epidemiology Branch, DCEG
- Recently served as the principal investigator for the etiologic component of the 155,000-person NCI Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
- Led recent *Connect for Cancer Prevention* team and an interagency, multidisciplinary team of collaborators to track and visualize COVID-19 Seroprevalence Studies

Released June 2022

- Quitting smoking is among the most effective treatment options for improving the likelihood of survival, quality of life, and overall health of people with cancer who smoke
- Scientific editorial committee:
 - Timothy Baker, PhD
 - Michael Fiore, MD, MPH, MBA
 - Anne Joseph, MD, MPH
 - Monica Webb Hooper, PhD
 - Gordon Willis, PhD
- Tobacco Control Monograph #24 will focus on understanding the effects of alcohol use across the tobacco control continuum

> JCO Oncol Pract. 2022 Dec;18(12):e1971-e1976. doi: 10.1200/OP.22.00385. Epub 2022 Nov 7.

Treating Smoking in Cancer Patients: An Essential Component of Cancer Care—The New National Cancer Institute Tobacco Control Monograph

Douglas R Lowy¹, Michael C Fiore^{2,3}, Gordon Willis¹, Kristen N Mangold¹, Michele H Bloch¹, Timothy B Baker^{2,3}

NCI TOBACCO CONTROL MONOGRAPH SERIES

23

Treating Smoking in Cancer Patients: An Essential Component of Cancer Care

Cessation Strategies
Medications Counseling

NCI's Smokefree.gov Initiative (SFGI)

- SFGI offers a suite of free **web- and mobile-based smoking cessation resources** that provide evidence-based information and support to people who use tobacco and want to quit
- Smokefree.gov resources reached **~7-8 million** people in 2022
- Now developing resources to support cessation of menthol tobacco products for African Americans and other groups who disproportionately use these products
- Recent accomplishments:
 - [National Text Portal](#) (launched March 2022)
 - SmokefreeTeen – [Next Legends](#) landing page (launched May 2022)
 - Expansion of SmokefreeTeen Vaping Cessation resources
 - SFGI reached its 20th anniversary, SFGI-VA SmokefreeVET Collaboration, and SFGI-CDC Collaboration reached its 10th anniversary

FDA Updates

Menthol in Cigarettes & Cigars

- In April 2022, FDA issued a [news release](#) proposing product standards to prohibit menthol as a characterizing flavor in cigarettes and prohibit all characterizing flavors (other than tobacco) in cigars
- The public comment period closed August 2022

Non-Tobacco Nicotine Products

- On March 17, 2023, the FDA issued two notices updating the definition of “tobacco product” in its existing [regulations](#) and [guidances](#)
- These new guidelines amend the April 14, 2022 federal law that was passed in response to the increase of non-tobacco nicotine in popular tobacco products


Potential Nicotine Standard

- **Ongoing:** the FDA is working to develop a proposed product standard that would establish a maximum nicotine level to [reduce the addictiveness of cigarettes](#) and certain other combusted tobacco products

Alcohol Causes Increased Risk of Cancer at Seven Sites and is the Number Three Modifiable Risk Factor for Cancer


NATIONAL CANCER INSTITUTE

Cancers Associated with Drinking Alcohol



cancer.gov/alcohol-fact-sheet

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States



CA A Cancer J Clinicians, Volume: 68, Issue: 1, Pages: 31-54, First published: 21 November 2017

Alcohol and Cancer

- NCI research areas include communication and awareness related to alcohol and cancer, such as uncertainty and complexity in relation to alcohol, cancer, and health outcomes at multiple levels; and decision-making processes and evaluation of the effects of warning labels and other communication strategies
- Relevant funding opportunities
 - Alcohol and Cancer Control (NOT-CA-20-034)
 - Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes (NOT-AA-21-028)

Open Access Article

Awareness of Alcohol and Cancer Risk and the California Proposition Warning Sign Updates: A Natural Experiment

by Alexandra Budenz¹, Richard P. Moser², Raimee Eck³, Tanya Agurs-Collins³, Timothy S. McNeel⁴, William M. P. Klein² and David Berrigan^{3,*}

American Journal of Preventive Medicine

RESEARCH ARTICLE

Awareness of Alcohol as a Carcinogen and Support for Alcohol Control Policies

Andrew B. Seidenberg, PhD, MPH¹, Kara P. Wiseman, PhD, MPH², Raimee H. Eck, PhD, MPH³, Kelly D. Blake, ScD¹, Heather N. Plattner, PhD, MS¹, William M.P. Klein, PhD²

This activity is available for CME credit. See page A3 for information.

Introduction: Alcohol use increases cancer risk, yet awareness of this association is low. Alcohol control policies have the potential to reduce alcohol-related cancer morbidity and mortality. Research outside the U.S. has found awareness of the alcohol-cancer link to be associated with support for alcohol control policies. The purpose of this study is to estimate the prevalence of support

VIEWPOINT

Alcohol and Cancer Risk: Clinical and Research Implications

William M. P. Klein, PhD
Behavioral Research Program, National Cancer Institute, Bethesda, Maryland.

Paul B. Jacobsen, PhD
Healthcare Delivery Research Program, National Cancer Institute, Bethesda, Maryland.

Kathy J. Helzlsouer, MD, MHS
Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland.

Ample evidence has been available for some time indicating that alcohol use is a preventable risk factor for cancer, and the World Health Organization deemed alcohol a carcinogen more than 30 years ago. In the United States, it is estimated that 5.6% of incident cancer cases (approximately 87 000 each year) are associated with alcohol, including cancers of the oral cavity, pharynx, larynx, liver, esophagus (squamous cell carcinoma), female breast, and colorectum.¹ Type of alcohol does not appear to matter; all alcoholic beverages include ethanol, which increases levels of acetaldehyde and in turn promotes DNA damage. Moreover, even moderate levels of consumption (often defined as approximately 14.28 g/d, the equivalent of about 1.2 drinks) appear to be associated with higher risk of some cancers, including cancers of the female breast.² A protective as-

As the mechanisms and recollections of cancer, empirical effects of moderate alcohol consumption, pooled analyses of consumers in the United States, increased risk of cardiovascular disease, and exclusion of alcohol from a protective response relationship, that suggest between alcohol

Concise Research Report | Published: 10 September 2021

Clinician Role in Patient Awareness Regarding Carcinogenic Nature of Alcohol Consumption in the US: a Nationally Representative Survey

Original Investigation | Substance Use and Addiction

Association Between Daily Alcohol Intake and Risk of All-Cause Mortality: A Systematic Review and Meta-analyses

Jinhui Zhao, PhD; Tim Stockwell, PhD; Tim Naimi, MD; Sam Churchill, MSc; James Clay, MSc; Adam Sherer, PhD

CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION | MINIREVIEW

Alcohol and Cancer: Existing Knowledge and Evidence Gaps across the Cancer Continuum

Susan M. Gapstur¹, Elisa V. Bandera², David H. Jernigan³, Noelle K. LoConte⁴, Brian G. Southwell⁵, Vasilis Vasiliou⁶, Abenaa M. Brewster⁷, Timothy S. Naimi⁸, Courtney L. Scherr⁹, and Kevin D. Shield^{10*}

ABSTRACT

NIH NATIONAL CANCER INSTITUTE
Division of Cancer Control and Population Sciences

Alcohol as a Target for Cancer Prevention and Control: Research Challenges.

Virtual webinar
December 18, 2020



Do Beliefs about Alcohol and Cancer Risk Vary by Alcoholic Beverage Type and Heart Disease Risk Beliefs?


Andrew B Seidenberg¹, Kara P Wiseman², William M P Klein¹

Affiliations + expand

PMID: 36453075 PMID: PMC9839574 (available on 2023-07-09)

DOI: 10.1158/1055-9965.EPI-22-0420

- Results illustrate a lack of awareness that alcohol is a risk factor for cancer
- Many believe that current labeling is not sufficient; a petition has been signed by various professional associations and societies, advocating for rotating warning labels



Weighted proportion of US American adults' beliefs about how wine, beer, and liquor consumption affect cancer risk (error bars $\frac{1}{4}$ 95% CI)


Current Label

GOVERNMENT WARNING:

(1) According to the Surgeon General, women should not drink alcoholic beverages during pregnancy because of the risk of birth defects. (2) Consumption of alcoholic beverages impairs your ability to drive a car or operate machinery, and may cause health problems.

Changes in the Cannabis Landscape

- As of April 2023, 38 states, four territories, and the District of Columbia allow the medical use of cannabis products. In addition, 23 states, two territories, and the District of Columbia have enacted measures to regulate cannabis for adult non-medical use
- The National Academies of Sciences, Engineering, and Medicine (NASEM) is developing a report that will provide an objective and authoritative account of the experiences in states and localities in the United States that permit medical or non-medical (adult use) of cannabis and cannabinoids
- The final report is tentatively scheduled for a fall 2024 release



2017 NASEM Report

The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis

Advancing Adolescent Tobacco Cessation Intervention Research

RFA-CA-22-042; RFA-CA-22-043

- Expires October 16, 2023; NCI and NIDA participating
- The RFAs will support research to develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on mid- to late adolescence (approximately 14-20 years old)
- Studies of interest include those that:
 - Promote cessation of non-cigarette tobacco products (e.g., electronic nicotine delivery systems (ENDS), cigars, smokeless tobacco)
 - Promote cessation in the context of dual and poly tobacco use
 - Are tailored to subpopulations with elevated tobacco use rates (e.g., African American youth, American Indian/Alaska Native youth, LGBTQ youth, and youth with mental health conditions)



Pre-Application Webinar – provided information about the companion Requests for Applications (RFAs), [RFA-CA-22-042](#) (R34 Clinical Trial Optional) and [RFA-CA-22-043](#) (R01 Clinical Trial Required)

Webinar materials available



Administrative Supplements to Existing Patterns of Tobacco and Cannabis Use; *NOT-CA-22-070*

- Expired May 27, 2022
- Project titles:
 - Characterizing cannabis use and its impact on smoking cessation socioeconomically disadvantaged adults participating in cessation treatment (PI: Kendzor)
 - Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial (PI: McClure)
 - Optimized chronic care for smokers: Developing and implementing integrated clinical and systems interventions in primary care (PI: Fiore)
 - Predicting and understanding the use of nicotine products in a rapidly evolving nicotine marketplace: The International Nicotine Product, Policy, and Market (INPAM) Study (PI: Cummings)
 - ENDS use trajectories from adolescence through young adulthood: A longitudinal study of risk factors and profiles (PI: Harrell)



Questions related to **cannabis** will be added to the next wave of the [Health Information National Trends Survey](#), an NCI-funded and BRP-led nationally representative survey collecting data about the American public's knowledge of, attitudes toward, and use of cancer- and health-related information

Selected CRAN-Relevant Funding Opportunities

Shortened Title	Announcement #	Expires	Contact
Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities	RFA-OD-23-015	June 20, 2023	Maria Roditis 240-276-5326 maria.roditis@nih.gov
Tobacco Control Policies to Promote Health Equity	PAR-20-302 PAR-20-303	September 08, 2023	Margaret Mayer 240-276-6433 margaret.mayer@nih.gov Annette Kaufman 301-467-8521 kaufmana@mail.nih.gov
Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes	NOT-AA-21-028	September 08, 2024	Carolyn Reyes-Guzman 240-276-7244 carolyn.reyes-guzman@nih.gov
Mentored Research Scientist Career Development Award in Tobacco Regulatory Research	RFA-OD-22-023 RFA-OD-22-024	March 13, 2025	Rachel Grana Mayne 240-276-5899 rachel.mayne@nih.gov
Advancing Adolescent Tobacco Cessation Intervention Research	RFA-CA-22-042 RFA-CA-22-043	October 16, 2023	

Selected CRAN-Relevant Funding Opportunities, cont'd.

Shortened Title	Announcement #	Expires	Contact
Pathway to Independence Award in Tobacco Regulatory Research	RFA-OD-22-025 RFA-OD-22-026	March 13, 2025	Rachel Grana Mayne 240-276-5899 rachel.mayne@nih.gov
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects	NOT-OD-22-023	May 09, 2024	Rachel Grana Mayne 240-276-5899 rachel.mayne@nih.gov
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects	NOT-OD-22-022	May 09, 2023	Ron Johnson 240-276-6250 rjohnso2@mail.nih.gov
Notice of Special Interest (NOSI): Alcohol and Cancer Control	NOT-CA-20-034	September 09, 2023	Tanya Agurs-Collins 240-276-6956 collinsta@nih.gov David Berrigan 240-276-6752 berrigad@nih.gov

Resources

hints.cancer.gov

Save the Date: 2023 HINTS Data Users Conference



Bringing Health Communication Data to Life

Save the Date for the 2023 HINTS Data Users Conference — Celebrating 20 Years of HINTS

Conference Dates: September 21-22, 2023

Conference Location: Natcher Conference Center (Building 45), NIH Main Campus, Bethesda, MD

Additional information about the conference, including registration information, will be coming soon.

September 21-22, 2023

**Location: Natcher Conference Center, NIH
Bethesda, MD**

Website: [HINTS meetings & trainings](#)

Abstracts due May 31, 2023

cancercontrol.cancer.gov/tus-cps



Tobacco Use Supplement
Current Population Survey

SECTION MENU

- TUS-CPS FAQs
- TUS-CPS Linkages
- TUS-CPS Publication Database
- TUS-CPS Publications
- TUS-CPS Questionnaires and Data Files
- TUS-CPS Survey Topics
- TUS-CPS Translations
- User Workshops & Webinars

RESEARCH ARTICLES | OCTOBER 04 2022

Menthol Cigarette Smoking Trends among United States Adults, 2003-2019 ✓

Elizabeth L. Seaman ; Nalini Corry ; Joanne T. Chang ; Dana Chomenko ; Anne M. Hartman ;
Derrine Lawrence Kitzner ; Carolyn M. Reyes-Guzman

Check for updates



Get in touch!

Website: cancercontrol.cancer.gov/brp

Twitter: [@NCIBehaviors](https://twitter.com/NCIBehaviors)

Newsletter: cancercontrol.cancer.gov/brpsubscribe



William Klein, Ph.D.

Associate Director

Behavioral Research Program

Division of Cancer Control and Population Sciences

National Cancer Institute

kleinwm@mail.nih.gov

Meet our staff online and contact Program Directors:

<https://staffprofiles.cancer.gov/brp/prgmStaffHome.do>



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol